studies

breast cancer - HER2-positive, HER inhibitor vs. non active control, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsTEACH (EGF105485), 2013 0.99 [0.74; 1.32] 0.99[0.74; 1.32]TEACH (EGF105485), 201310%3,147NAnot evaluable iDFSdetailed resultsExteNET, 2016 0.67 [0.50; 0.90] 0.67[0.50; 0.90]ExteNET, 201610%2,840NAnot evaluable RFS/DFSdetailed resultsExteNET, 2016 0.63 [0.47; 0.85] TEACH (EGF105485), 2013 0.83 [0.69; 0.99] 0.74[0.57; 0.97]ExteNET, 2016, TEACH (EGF105485), 2013258%5,987moderatenot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-11-05 19:14 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 712,429,903,472,969,902,1321,643,641,640,427,910,430,976,909,966,917,1013,1025,916,977,1029,1017,911,428,971,913,912,918,965,1067,978,915,914,973,974,702,1313,498,1314,368,1301,1412,1298,1299,1334,1332,1303,1325,1320,1305,1300,1429,1324,1335,1307,1322,1319,718,422,1304,421,1312,1326,1368,1373,1309,1302,1308